FLT3 and acute myeloid leukemia: There was no difference in survival between AML patients with FLT3‐ITD and patients with wild‐type FLT3, but in cases not receiving allo‐HSCT, FLT3‐ITD was associated with a significantly reduced OS, illustrating that allo‐HSCT might overcome the adverse effect of FLT3‐ITD on the survival of AML patients.